Related Articles
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours
HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I− tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours